arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

C4 Therapeutics, Inc.

CCCC

$3.73 ▲ +0.08 (+2.33%) at close

8 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

C4 Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $309.2M

Dividend Yield —

Revenue Growth 1.0% ↘

Op. Margin -320.5% ↗

ROIC -45.0% ↗

FCF / Share $-1.20 ↘

Trailing P/E —

Price / Book 1.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$35.95M

↑ +1.0% —

Net Income Profit after all expenses

$-104.99M

— +0.3% —

Operating Margin Operating profit as % of sales

-320.5%

↑ +4.6% 0th

FCF / Share Free cash flow per share

$-1.20

↓ -27.2% —

Long-Term Debt Long-term obligations

$0.00

↓ -100.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	1.0% Caution ↓ Caution Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-87%)	71.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+793%)	-33.3% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-516%)	—	—	—	—	—
EPS Growth YoY (%)	16.4% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	43.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-1.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-44.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	68.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	81.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	0.3% Caution ↑ Caution Improving Year-over-year change in net income	20.5% Good ↑ Good Improving Year-over-year change in net income	-3.4% Weak ↑ Weak Improving Year-over-year change in net income	-52.8% Weak ↑ Weak Improving Year-over-year change in net income	-26.5% Weak Weak Year-over-year change in net income	-94.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-27.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	56.9% Excellent Excellent Year-over-year change in free cash flow	4.1% Caution Caution Year-over-year change in free cash flow	—	—	—	—	—
Revenue CAGR 3Y (%)	5.0% Caution Caution Compound annual revenue growth over 3 years	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Operating Margin (%) (%)	-320.5% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2237%)	-336.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2341%)	—	-416.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2877%)	—	—	—	—
Effective Tax Rate (%) (%)	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	0.9% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-2.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	-292.1% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2534%)	-296.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2566%)	—	-412.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3535%)	—	—	—	—
FCF Margin (%) (%)	-276.2% Weak → Weak Stable Free cash flow as a percentage of revenue Optimal: > 10%	-183.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	-358.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.62x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	-1.59x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-45.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-55.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-57.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-43.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-16.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-20.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	32.4% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-32.1% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-34.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-36.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-30.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-15.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-30.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-40.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-373%)	-48.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-425%)	-53.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-459%)	-44.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-395%)	-21.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-244%)	-23.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-257%)	30.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+103%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Debt to Equity (x)	—	—	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.04x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-93%)	0.03x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-95%)	0.04x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-94%)	—	—
Interest Coverage (x)	—	—	-140.44x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-79.76x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-62.79x Weak Weak Operating income divided by interest expense Optimal: > 5x	-73.72x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-74.60M	$-55.50M	$-126.59M	$-18.27M	$-65.36M	$-171.68M	$-90.55M	—
Debt / EBITDA (x)	—	—	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.09x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.13x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.17x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$0.43	$0.51	$0.42	$0.64	—	—	—	—
Basic EPS, GAAP (USD)	$-1.27	$-1.52	$-2.67	$-2.62	$-1.82	$-5.83	$-31.03	—
Free Cash Flow per Share (USD)	$-1.20	$-0.94	$-2.19	$-2.28	—	—	—	—
Book Value per Share (USD)	$2.65	$3.06	$4.07	$5.91	$8.00	$6.52	$-78.48	—
Tangible Book Value per Share (USD)	$2.65	$3.06	$4.07	$5.91	$8.00	$6.52	$-78.48	—
Basic Weighted Avg Shares (shares)	82.89M	69.37M	49.64M	48.86M	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$225.08M	$212.59M	$228.42M	$243.01M	$274.44M	$337.16M	$63.13M	—
LT Debt (USD)	—	—	$0.00	$11.48M	$10.77M	$10.05M	—	—
Total Equity (USD)	$256.59M	$215.99M	$246.11M	$289.23M	$389.61M	$280.79M	$-111.96M	$-79.75M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$35.95M	$35.58M	$20.76M	$31.10M	—	—	—	—
Depreciation Expense (USD)	$1.54M	$1.47M	$1.58M	$1.68M	$1.49M	$1.62M	$1.59M	—
Net Income, GAAP (USD)	$-104.99M	$-105.32M	$-132.49M	$-128.18M	$-83.89M	$-66.33M	$-34.10M	—
Operating Cash Flow (USD)	$-98.69M	$-65.16M	$-106.84M	$-105.94M	$-86.97M	$-67.25M	$55.61M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 29 quarters

C4 Therapeutics, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CCCC with peers